Bryn Mawr Trust CO Ultragenyx Pharmaceutical Inc. Transaction History
Bryn Mawr Trust CO
- $5.48 Billion
- Q3 2024
A detailed history of Bryn Mawr Trust CO transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 1,489 shares of RARE stock, worth $62,642. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,489Holding current value
$62,642% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RARE
# of Institutions
324Shares Held
85.6MCall Options Held
520KPut Options Held
406K-
Vanguard Group Inc Valley Forge, PA9.95MShares$418 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$236 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$215 Million0.91% of portfolio
-
Wellington Management Group LLP Boston, MA4.17MShares$175 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$129 Million0.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.95B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...